Abstract

Methods: This was a randomized, open-label, parallel-group study conducted in a tertiary care teaching hospital in which 100 hypertensive patients were randomly assigned to receive either cilnidipine (20 mg/day) or telmisartan (40 mg/day) for a period of 12 weeks. The primary endpoint of the study was the change in mean systolic blood pressure (SBP) from baseline to 12 weeks. The secondary endpoints included the change in mean diastolic blood pressure (DBP), heart rate, and adverse events. Results: At the end of the study, the mean SBP and DBP decreased significantly in both groups compared to baseline (p<0.001). However, the reduction in mean SBP was significantly higher in the cilnidipine group (22.7±8.2 mmHg) compared to the telmisartan group (18.9±7.5 mmHg) (p=0.005). The reduction in mean DBP was similar in both groups (cilnidipine: 12.3±5.2 mmHg; telmisartan: 11.7±4.8 mmHg) (p=0.56). There was no significant difference in heart rate between the two groups. Adverse events were mild and similar in both groups. Conclusion: In hypertensive patients attending a tertiary care teaching hospital, cilnidipine was found to be more effective than telmisartan in reducing systolic blood pressure. Both drugs were well-tolerated, and adverse events were mild and similar in both groups. Further studies are needed to confirm these findings and to investigate the long-term effects of these drugs in the management of hypertension

Description

.